drugset
drugset / Trial / NCT04292535

Safety and Efficacy of Combining Intranasal Insulin & Acute Exercise

NCT04292535 ↗

Phase 2 Completed 116 enrolled Michigan State University
RandomizedParallel-groupDouble-blindTreatment

Summary

To determine if physical activity engagement alters the dose-response profile and safety of administration of insulin into the intranasal mucosa.

Timeline

Start
2018-06-15
Primary completion
2020-02-20
Completion
2020-02-20

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject insulin aspart Protein / enzyme biologic 20 iu Intranasal
Subject insulin aspart Protein / enzyme biologic 40 iu Intranasal
Subject insulin aspart Protein / enzyme biologic 60 iu Intranasal
Subject insulin aspart Protein / enzyme biologic 80 iu Intranasal
Subject insulin aspart Protein / enzyme biologic 100 iu Intranasal
Subject insulin aspart Protein / enzyme biologic 120 iu Intranasal

Indications

No indication recorded.